- Home
- JANX vs AGNT Comparison
JANX vs AGNT Comparison
Compare JANX & AGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.64
Company Overview
Basic Information| Metric | JANX | AGNT |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 840.4M | 778.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | JANX | AGNT |
|---|---|---|
| Price | $14.64 | $5.22 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $47.00 | N/A |
| AVG Volume (30 Days) | 845.1K | ★ 1.5M |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $4.51 |
| 52 Week High | $35.34 | $4.81 |
Technical Indicators
Market Signals| Indicator | JANX | AGNT |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | N/A |
| Support Level | $13.13 | N/A |
| Resistance Level | $15.49 | N/A |
| Average True Range (ATR) | 0.57 | 0.00 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 84.78 | 0.00 |
Price Performance
Historical Comparison JANX
AGNT
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.